ImmuCell Corporation (ICCC)
undefined
undefined%
At close: undefined
4.92
-0.81%
After-hours Dec 13, 2024, 04:00 PM EST

Company Description

ImmuCell Corporation, an animal health company, develops, manufactures, and markets products that enhance the health and productivity of dairy and beef cattle in the United States and internationally.

It offers First Defense, an orally delivered scours preventive product for newborn dairy and beef calves; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus.

The company also provides California Mastitis Test that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, including a whey protein concentrate for the nutritional and feed supplement markets.

In addition, it is involved in developing Re-Tain, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows.

It sells its products through animal health distributors.

ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.

ImmuCell Corporation
ImmuCell Corporation logo
Country United States
IPO Date May 5, 1987
Industry Biotechnology
Sector Healthcare
Employees 75
CEO Michael F. Brigham

Contact Details

Address:
56 Evergreen Drive
Portland, Maine
United States
Website https://immucell.com

Stock Details

Ticker Symbol ICCC
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0000811641
CUSIP Number 452525306
ISIN Number US4525253062
Employer ID 01-0382980
SIC Code 2835

Key Executives

Name Position
Michael F. Brigham President, Chief Executive Officer, Principal Financial Officer, Treasurer, Secretary & Director
A. Gustavo Scaffa Senior Director of Quality
Bobbi Jo Brockmann Vice President of Sales & Marketing and Director
Elizabeth L. Williams Vice President of Manufacturing Operations
Elizabeth S. Toothaker Director of Finance & Administration and Controller
John W. Zinckgraf Director of Product Development

Latest SEC Filings

Date Type Title
Dec 09, 2024 8-K Current Report
Dec 02, 2024 8-K Current Report
Nov 13, 2024 10-Q Quarterly Report
Nov 13, 2024 8-K Current Report
Oct 08, 2024 8-K Current Report
Sep 24, 2024 8-K Current Report
Sep 24, 2024 4 Filing
Sep 24, 2024 4 Filing
Sep 24, 2024 4 Filing
Sep 24, 2024 4 Filing